Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that a single application of TCDD on the skin of hairless mice altered epidermal differentiation, changing keratin expression patterns similarly to a known tumor promoter.

This review summarizes findings on the long-term use of tofacitinib for severe alopecia areata, reporting its potential as a promising treatment option.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

This study found that in mice with deregulated β-catenin and PTEN signaling, increased follicular hyperplasia and sebaceous gland changes occur, but typical papillomas do not develop, potentially due to p21 response and reduced stem cell markers.

This study found that topical application of TSG from Polygonum multiflorum promoted hair regrowth in depilated mice, potentially through the inhibition of apoptosis-related proteins.

A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.

This report describes an 8-year-old male with trichotillomania, confirmed by trichoscopy showing characteristic hair damage and patterns.

This study found that topical application of TGF-β mimic promoted enhanced wound healing and tissue regeneration in mice, suggesting its potential as a therapeutic option for improving wound healing.

This study in Mexican adolescents with severe alopecia areata reported that oral tofacitinib treatment resulted in hair growth and reduced alopecia severity without serious adverse effects.

This study found that taurine significantly mitigated DHT-induced androgenetic alopecia in male C57BL/6 mice by promoting hair regrowth, enhancing hair follicle cycle progression, reducing apoptosis, and downregulating key androgen-related signaling pathways, highlighting its potential as a therapeutic candidate for hair loss management.

The Trichodysplasia spinulosa virus protein can cause abnormal hair growth in mice.

This letter discusses the limited treatment options for pediatric alopecia areata and the lack of controlled studies for therapies like systemic and off-label immunosuppressive drugs, without reporting new clinical results.

In this retrospective review, tofacitinib treatment was associated with clinically significant hair regrowth in most adolescent patients with alopecia areata, though limitations suggest further studies are needed to confirm these findings.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

The article in Dermatologic Therapy discusses clinical experiences with using tofacitinib to treat alopecia areata in 63 patients, but no specific results are reported in the abstract.

In this study, oral tofacitinib showed higher efficacy and tolerability in treating refractory alopecia totalis and universalis compared to traditional treatments, achieving a 50% improvement in severity scores for 44.4% of patients over six months, with fewer adverse effects.

This study found that oral tofacitinib at a 5mg twice daily dosage was effective in treating recalcitrant alopecia areata, showing significant improvement in hair regrowth and a 27% reduction in SALT scores over six months, with minimal side effects among the 19 patients monitored.

This study reported that topical drugs regrew hair in mice.

This study found that tofacitinib was an effective and well-tolerated treatment for alopecia areata, with significant to moderate hair regrowth in 78% of patients observed.

In this study, tofacitinib showed significant efficacy in treating alopecia totalis and universalis over a 6-month period, with notable hair regrowth outcomes, while younger age of onset and shorter treatment duration were linked to less effectiveness.

This study found that TPA was significantly more effective than mezerein in inducing dark basal keratinocytes in mouse skin, which may be important in early tumor promotion stages.

An arthritis drug helped a person with severe hair loss regrow their hair.

This case study reports that a 23-year-old woman with alopecia universalis experienced complete hair regrowth after six months of treatment with tofacitinib, a JAK-3 inhibitor.

This study found that a polyherbal formulation of Trigonella foenum-graecum seeds and Butea monosperma flowers significantly promoted hair growth and reduced dihydrotestosterone levels in a chemotherapy-induced alopecia model.

This study concluded that oral tofacitinib significantly improved hair growth in patients with alopecia areata, alopecia totalis, and alopecia universalis over a 24-week period, but longer studies are needed to assess long-term safety.

In this study, researchers identified nine cases of hair follicular tumors among 100 dog biopsy samples in Kerala, India, detailing subtypes like trichoblastoma and pilomatricoma, and analyzed their clinical, gross, and microscopic pathology.

This study identified a radio-resistant population of Krt15+ stem cells in the mouse small intestine that can initiate tumors, suggesting potential targets for colon cancer therapy.

This study reported that six out of seven pediatric patients with refractory patchy alopecia areata experienced significant hair regrowth after one month of oral tofacitinib treatment, suggesting it may be an effective and safe option, although larger studies are needed to evaluate long-term safety.

Finasteride may help reduce tic severity in male Tourette syndrome patients.

This study observed that colorectal cancer tumoroids adapted to an environment without a matrix by developing disordered self-assembly, but their tumor-specific phenotypes and drug sensitivity remained unchanged.